By Debra Z. Sabatini, RDH, BS, BA

Click here for original article.

Oral gel contains cancer-preventing compounds derived from black raspberries
Click Here for Original Article

By Maria Perno Goldie, RDH, MS, with the assistance of Allison Walker

Maria Perno Goldie (MPG): I had the opportunity to interview Dr. Susan Mallery, who is a humble as she is intelligent. I had the assistance of Allison Walker, a freelance journalist who has been involved in dental publishing for more than 20 years.

Dr. Susan Mallery (SM) is a Professor in the Division of Oral Surgery, Oral Pathology, and Anesthesiology at The Ohio State University, College of Dentistry, in Columbus, Ohio. Her research interests include oral cancer initiation, AIDS-related oral cancer and chemoprevention. Dr. Mallery has published articles in journals such as Cancer Research, Cancer Prevention Research, Molecular Pharmaceutics, Carcinogenesis and Clinical Cancer Research, to name a few.

She graduated from The Ohio State University with her DDS and later returned to receive her oral pathology specialty training and a PhD in Pathology. Dr. Mallery is licensed by the Ohio State Dental Board and board certified by the American Board of Oral Pathology and American Academy of Oral Pathology. She belongs to the American Academy of Oral Pathology, American Board of Oral Pathology, American Association for Cancer Research, and is a Fellow of the American Association for the Advancement of Science. She is a consultant at The Ohio State University and James Cancer hospitals.

MPG: Oral squamous cell carcinoma (OSCC) will be diagnosed in more than 36,000 Americans this year and has a particularly high mortality rate—as it will kill approximately 8,000 patients this year. As excisional surgery is the primary treatment for OSCC—even those patients who are cured suffer loss of tissues critical for esthetics, speech and eating. Due to OSCC’s high rates of morbidity and mortality and its high socio-economic impact, a strategy to prevent progression of precancerous oral lesions to OSCC is more appealing.

Currently, precancerous oral lesions are surgically removed—with either a blade or laser—and the tissues evaluated microscopically. Discouragingly, approximately 30% of lesions that are completely removed as confirmed by microscopic evaluation recur and some progress to OSCC. Dr. Mallery has dedicated her nearly 30-year career to studying new strategies to preventing oral cancer. Her research has been supported by funding from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) and The Ohio State University (OSU) Center for Clinical and Translational Science. It is also funded by the Fanconi Anemia Research Fund, a grassroots organization whose mission is to find effective treatments and a cure for Fanconi anemia and to provide education and support services to affected families worldwide. Dr. Mallery stresses that she is a part of a team, and that the research is truly a team effort.

Fanconi anemia (FA) is one of the inherited anemias that leads to bone marrow failure (aplastic anemia). It is a recessive disorder: if both parents carry a defect (mutation) in the same FA gene, each of their children has a 25% chance of inheriting the defective gene from both parents. When this happens, the child will have FA. Fanconi anemia patients have an extremely high risk of developing squamous cell cancers in areas of the body in which cells normally reproduce rapidly, such as the oral cavity, esophagus, the gastrointestinal tract, the anus, and the vulva. FA patients may develop these cancers at a much earlier age than people without Fanconi anemia.

Patients who have had a successful bone marrow transplant and, thus, are cured of the blood problems associated with FA, still must have regular examinations to watch for signs of cancer. Head and neck squamous cell carcinoma (HNSCC) is a significant threat for people

with FA, regardless of bone marrow transplantation status. Not only is the incidence of HNSCC considerably higher than in the general population (500-700 times higher), patients with FA present with these types of cancers at a younger age than those without FA – the median age is 27 years. Regular screenings are critically important.

MPG: Dr. Mallery, you have been investigating a number of agents to identify new therapeutics that can suppress the conversion of pre-cancerous to cancerous cells (chemoprevention), in particular, anthocyanins. Can you explain this to us?

SM: Chemoprevention is a way to prevent or delay the development of cancer by taking medicines, vitamins, or other agents. My colleagues and I are using a bimodal approach. Our first breakthrough was the creation of an oral gel containing high concentrations of anthocyanins, powerful cancer-preventing compounds found in black raspberries. Study results showed that the gel, when applied to the mouth, selectively removed atypical epithelial cells for the population through either preprogrammed cell death (apoptosis) or causing terminal differentiation (making the protective keratin covering).

MPG: Can you explain the mechanism of action of these anthocyanins?

SM: As briefly mentioned above, anthocyanins—and likely other black raspberry (BRB) compounds—are capable of modulating epithelial cell growth by affecting intracellular signaling and gene expression. Also apparent from our pilot study was that some patients derived more benefit from gel application. These inter-patient differences prompted a later study to help identify the cause.

Analyses of saliva samples collected after BRB rinses were conducted to assess local pharmacokinetics and compare the capacities of three different BRB rinse formulations to provide sustained intraoral levels of anthocyanins. Not surprisingly, these studies showed that BRB metabolism was affected by three intraoral enzymatic components, i.e. (1) oral tissues, (2) saliva, and (3) oral bacteria (“microflora”).

As all three components affected BRB bioactivation and local retention, it is likely inter-patient differences in these three areas that contribute in large part to BRB gel responsiveness. We are currently conducting the logical extension study of the pilot trial, which entails inclusion of a gel-placebo and multicenter testing. Results to date have confirmed therapeutic efficacy is limited to the BRB gel formulation and not the placebo. More complex analyses—which assess the gel’s effect at the molecular level—are ongoing.

One of the largest challenges with oral cancer chemoprevention is to develop an effective, yet nontoxic strategy. Efficacy speaks for itself—the need for nontoxic is tied to the fact that many to most of these treatments will be necessary for the life of the patient. The lifelong need is tied to the fact that persons who develop precancerous oral lesions have genetic mutations in the cells that are key for future epithelial generations, i.e., epithelial stem cells. When stem cells divide (which is not very often), they make perfect copies of themselves. Consequently, if the stem cells are mutated, their daughter cells faithfully carry forward this mutation. Our BRB gel data imply that locally applied black raspberry constituents can re-direct appropriate epithelial cell growth by removing mutated cells from the overall cell population. Consistent with a food-based approach, no systemic or local toxicities occurred.

Local delivery allows for better therapeutic concentration at the site with fewer systemic side effects. With oral cancer chemoprevention given systemically, the liver, in first-pass metabolism, makes the agent less active than the parent compound. The first-pass effect (also known as first-pass metabolism or presystemic metabolism) is a phenomenon of drug metabolism whereby the concentration of a drug is greatly reduced before it reaches the systemic circulation. It is the fraction of lost drug during the process of absorption that is generally related to the liver and gut wall. We must have a compliant patient population with local delivery, it is vital. In some cases the decision involves having multiple biopsies or applying a gel a number of times per day. Not having frequent biopsies can be a good motivator.

MPG: Dr. Mallery, you have been investigating alternatives to the surgical removal of pre-cancerous oral lesions. Can you explain what you have found in this area?

SM: We have turned our attention to identifying alternatives to the surgical removal of pre-cancerous lesions. However, we are not “there” yet. Close clinical follow up is critical. If we suspect a malignant lesion, we must first biopsy, and if it is an active lesion, place the gel to prevent recurrence.

MPG: Dr. Mallery went on to tell a story about her passion and her work in one of the studies. She related that one third of the patients in the pilot trial were “super” responders, lesions resolved clinically and histologically, and biochemical and molecular markers returned to normal after treatment. There was an intermediate group of about one third, and the last third did not respond in either a negative or positive way. The researchers wanted to determine what caused the “super” responders to react as they did. The study was done with normal, healthy people, and it was found that there is a large difference in variability in enzyme levels to recycle the product. Best responders bioactivate the product and keep it in place for a long time. Enzyme profiles are being done.

SM: Because BRB components alone are insufficient to regress some patients’ precancerous oral lesions, we have decided to introduce a second chemopreventive, the synthetic vitamin A compound, fenretinide. Fenretinide is a “bench” chemopreventive star capable of causing either differentiation or apoptosis in transformed epithelial cells. Previous fenretinide oral cancer chemoprevention trials, which relied on systemic fenretinide delivery, were unsuccessful. Although none of these studies assessed drug levels at the target site, the pill-based delivery format could not even achieve treatment-relevant blood levels. Furthermore, large systemic doses of fenretinide resulted in toxicities including night blindness and changes in blood lipid profiles.

The objective of this study was to enhance oral mucosal permeation of fenretinide by co-incorporation of propylene glycol (PG) and menthol in fenretinide/Eudragit RL PO mucoadhesive patches. Fenretinide is an extremely hydrophobic chemopreventive compound with poor tissue permeability. Co-incorporation PG or menthol in fenretinide/Eudragit RL PO patches led to significant ex vivo fenretinide permeation enhancement. Addition of PG above 2.5 wt% in the patch resulted in significant cellular swelling in the buccal mucosal tissues. These alterations were ameliorated by combining both enhancers and reducing the PG level.

After buccal administration of patches in rabbits, in vivo permeation of fenretinide across the oral mucosa was greater relative to permeation obtained from the enhancer-free patch. In vitro and in vivo release of fenretinide from the patch was not significantly increased by co-incorporation of permeation enhancers, indicating that mass transfer across the tissue, and not the patch, largely determined the permeation rate control in vivo. As a result of its improved permeation and its lack of deleterious local effects, the mucoadhesive fenretinide patch co-incorporated with 2.5 wt% PG + 5 wt% menthol represents an important step in the further preclinical evaluation of oral site-specific chemoprevention strategies with fenretinide.

Fenretinide was studied in pill form, where there was more drug in the blood versus at the site. There were also toxicity problems. My team and I always thought that fenretinide would be a good drug if delivered in a different manner.

I worked with Peter Larsen, DDS, Chair of Division, Oral Maxillofacial Surgeon, Gary Stoner, PhD, and Kashappa Goud Desai, PhD, in both trials. Steven P. Schwendeman, PhD, is a pharmaceutical chemist, Professor and Chair Department of Pharmaceutical Sciences, College of Pharmacy, at the University of Michigan. His lab developed the fenretinide patch with Kashappa-Goud Desai, PhD. Fenretinide is lipophillic, and they needed the formulation to be stable, for the patch to stick on the site, deliver drug, and allow the drug to penetrate in an aqueous environment into keratinized tissue. It is great science! These two researchers are involved with patent application for the fenretinide patch, to be placed on active or recently excised lesions.

A combination approach with these two chemotherapeutics may someday be achieved and they may be complementary or synergistic. They have different mechanisms of action and if delivered at the same time could be antagonistic. The dosing must be staggered, with initial application, and perhaps 12 hours later, delivery of the next drug. When the patch is applied to lesions, pharmacokinetic studies show no drug in the saliva. The hypothesis is for targeted delivery and uptake of fenretinide, followed by field coverage with the raspberry rinse. A published study stated that the objective was to develop fenretinide oral mucoadhesive patch formulations and to evaluate their in vitro and in vivo release performance for future site-specific chemoprevention of oral cancer. The gel was used topically at the site of the lesion or after excision.

Our goal is to create complementary oral cancer chemoprevention strategies that would permit targeted delivery directly to visible lesions as well as address the need for field coverage throughout the mouth. My colleagues and I are optimistic that optimized delivery formulations and dosing schedules for BRB and fenretinide will help make appreciable clinical progress. We aim to prevent cancerization, which is transformation of cells into cancer, or from a normal to a cancerous state.

The concept is that being exposed to toxins and metabolic enzymes can activate toxins and cause the mutated cells to become active. There is now a multi-centered NCI trial of the raspberry product in patients, based on the pilot study. There are two manuscripts, one published and one pharmacokinetic study in rabbits ready to be published. The patch is considered a device by the FDA and they must apply as an Investigational New Device (IND). It is a very safe drug.

MPG: Dr. Mallery, what is your advice about prevention of oral cancers?

SM: I recommend not using tobacco in any form, using alcohol in moderation, visiting an oral healthcare provider at least every six months, practicing good oral hygiene, living a healthy lifestyle, having good nutrition, and providing immunization against the human papillomavirus (HPV) for sons and daughters. Precancerous lesions (oral dysplasia) tend to be on the floor of mouth, lateral border of the tongue, etc. The raspberry gel is sticky, and we are trying to get the adherent patch dosage as a “burst delivery” every 15 minutes. Patients are told not to eat or drink for 30 minutes, and the patch is designed for use multiple times throughout the day. It will be a prescription agent. Research has been conducted in Dr. Schwendeman’s lab on oral cancer patients with polyglycolic acid and polylactic acid implants (properties similar to resorbable sutures) that can deliver drug in the former cancer site. We know our patient population, they may not apply something four times a day. Polymeric implants for cancer chemotherapy may be one of the answers.

MPG: I want to thank Dr. Mallery for her time and expertise. I also wish to thank Allison Walker for her assistance with this interview.

Additional reading

1. www.fanconi.org/index.php/learn_more.

2. www.fanconi.org/index.php/learn_more/relationship_to_cancer.

3. www.mdanderson.org/patient-and-cancer-information/cancer-information/cancer-topics/prevention-and-screening/chemoprevention/index.html.

4. Mallery SR, Budendorf DE, Larsen MP, Pei P, Tong M, Holpuch AS, Larsen PE, Stoner GD, Fields HW, Chan KK, Ling Y, Liu ZEffects of human oral mucosal tissue, saliva, and oral microflora on intraoral metabolism and bioactivation of black raspberry anthocyanins. Cancer Prev Res (Phila) 4(8) 1209-21 8/1/2011.

5. en.wikipedia.org/wiki/First_pass_effect.

6. Wu X, Desai KG, Mallery SR, Holpuch AS, Phelps MP, Schwendeman SP. Mucoadhesive Fenretinide Patches for Site-specific Chemoprevention of Oral Cancer: Enhancement of Oral Mucosal Permeation of Fenretinide by Co-incorporation of Propylene Glycol and Menthol. Mol Pharm. 2012 Jan 26. [Epub ahead of print].

7. Goodman A. Moving Chemoprevention Forward into the Most Promising Areas of Study. Aerodigestive, Gynecologic, Prostate, & Bladder Cancers. Oncology Times, March 10, 2003 – Volume 25 – Issue 5, p 25-26.

8. Holpuch AS, Desai KH, Schwendeman SP, Mallery SR. Optimizing therapeutic efficacy of chemopreventive agents: A critical review of delivery strategies in oral cancer chemoprevention clinical trials. J Carcinog 2011; 10:23)

9. Desai KH, Mallery SR, Holpuch AS and Schwendeman SP. Development and In Vitro-In Vivo Evaluation of Fenretinide-Loaded Oral Mucoadhesive Patches for Site-Specific Chemoprevention of Oral Cancer. Pharmaceutical Research, Volume 28, Number 10, 2599-2609. (www.springerlink.com/content/h54g2w4835031l5x/)

Maria Perno Goldie, RDH, MS

To read previous articles in RDH eVillage FOCUS written by Maria Perno Goldie, go to articles.

CANCER, that word carries heavy meaning and emotion.

Cancer touches most of us by personal experience and / or how the disease affects the life of a family member or friend. Cancer and Saint Peregrine fit together. Saint Peregrine is the Patron of those afflicted with cancer.

Cancer carries negative emotions.
Saint Peregrine promises HOPE.

A Healing Prayer Service will be held Sunday, April 29, 2012

Beginning at 2:00pm

at the

Church of the Transfiguration

972 South Miami Street

West Milton, Ohio 45383

www.transfigurationonline.com

The Healing Prayer Service is particularly planned for those who have cancer and for those who love and care for them.  The service will include an opportunity to see, hold and touch a First Class Relic of Saint Peregrine, Patron of those afflicted with cancer.  All who have cancer and all those concerned for someone with cancer are welcome to attend.

No reservations required.

The prayer service is expected to take just over an hour or slightly longer.

Cookies, punch and conversation will be available afterword in the Church Social Hall.

This Healing Service is being provided by the St. Peregrine Cancer Ministry of the Church of the Transfiguration in cooperation with the Sisters of the Precious Blood at the Maria Stein Shrine of the Holy Relics.   http://www.mariasteinshrine.org/

You do not have to be Catholic or Christian to attend!  ALL ARE WELCOME!

The Church of the Transfiguration is located in West Milton, Ohio, approximately
7 miles north of I-70 ( Exit 29 ) on Ohio Route 48.

For more information, please contact Hank or Lil Deneski 937-832-2677

The Foundation of Young People Against Cancer Ecuador is a non-profit organization based in Quito-Ecuador. The Foundation’s mission is to help young people who suffer cancer to be able to access to important health programs, proper care and additional information, and activities that improve their lives and self-esteem while they are living with cancer.

Location: Quito – Ecuador

Date: May 4-8, 2012

Free registration is available at their website:

http://www.jovenescontraelcancer.org/

Information About the Conference

FORMS OF TREATMENT, THE GOVERNMENT SUPPORT, FAMILY, SOCIAL AND ATTITUDES ARE DIFFERENT IN EACH COUNTRY
In February 2010, the Youth People Foundation Against Cancer organized the 1st. International Meeting for Young People with
Cancer and Survivors, bringing together 112 soldiers from 12 countries and 3 continents. The foundation has become an important contribution to national and international community and visit different countries like Colombia, Mexico, Argentina, Venezuela, Uruguay and Peru.

OBJECTIVES:
Develop a statement which young people with cancer of the World present their proposals to the treatments, priorities, rights
and public health policies.

SHARING STRATEGIES, SKILLS AND EXPERIENCE THAT EVERY ORGANIZATION IMPLEMENTED IN THEIR OWN COUNTRY FOR THE INTEGRAL DEVELOPMENT OF YOUTH PEOPLE IN TREATMENT.

TO WHO:

• Men and Women
• Youth between 17 and 30 years of age diagnosed with cancer and survivors.

FREE REGISTRATION
www.jovenescontraelcancer.org

• The costs of accommodation, food and transportation in Ecuador will be covered for the Foundation.
• Requires pre-fill the registration form.

POLICY FOR SCHOLARSHIPS:

• It will be considerate the economic situation of the each young people. It will be a priority to young people from developing countries and the commitment to the sponsoring organization.
• Scholarships are limited to 25%, 50% and 75% of airline ticket

Apply immediately

JUSTIFICATION OF THE CONVENTION

1. The lack of infrastructure and information directed to young people with cancer which affects the knowledge and increasing abandonment of treatment.
2. The discrimination which affects so many young people in various aspects such as: economic, social, medical and psychological, limiting a good quality of life.
3. The lack of palliative care, debts and psychological support to caregivers are real concerns in advanced stages.
4. The Self-esteem of young people tends to fall in response to side effects of treatments (hair loss, weakness, isolation, nausea, etc.)
5. The economic dependence of young people, between 14 and 21 years of age, because normally they do not work and study and consequently do not have their own income.
6. Amputations and transplants affect them physically, financially, emotionally and socially.
7. The lack of psycho-oncologists, pediatric oncologists, surgeons and other specialists in the area of children and adolescents, is a vital necessity.

BENEFITS FOR YOUTH ATTENDING THE CONVENTION

1. To develop leadership skills, encourage social networking among young participants.
2. Create, share, tips, themes and projections to jointly tackle the disease as rituals for warriors, photography workshops, gladiators of hope, ambassadors of joy and other ongoing projects.
3. Better manage the side effects of chemotherapy, radiotherapy, treatment and survival.
4. Tend to make society aware of the problem of cancer in young people, respect and provide opportunities to study, work and develop normally.
5. Encourage public authorities and institutions dedicated to youth to truly support projects for young people with cancer.

METHODOLOGY OF THE CONVENTION

• Young people will be organized in groups classified by diagnosis: Leukemia, ALL, AML, sarcoma, lymphoma, brain, osteosarcoma and other.
• Each group will issue a document with the main recommendations of their disease.
• There will be activities and workshops for groups and in general as dynamics, movies, forums, outings and lectures.

We wanted to share the great news with our readers that there is a Free Cancer Screening coming up in Dallas!

Free Oral Cancer Screening in Dallas

This “Head & Neck Check” is Saturday, April 28, from 8:30AM until 11AM. It takes place at the New Baylor Charles A. Sammons Cancer Center at Dallas. The address is 3410 Worth Street, Suite 250 in Dallas, Texas 75246.

This screening opportunity does not require an appointment, and you can reach the facility by taking the DART Green Line to the Baylor University Medical Center at Dallas stop.

You can find more information about this event by visiting BaylorHealthcare.com/DallasCancer.

We hope that everyone interested in an Oral Cancer Screening can make it out. Take care of yourself or your loved ones in need and get checked out now!

With Oral Cancer Awareness month just around the corner, we wanted to post a link to a great article about the importance of early intervention in Oral Cancer Prevention and treatment. According to an article by Debra Z. Sabatini, RDH, BS, BA, “We can decrease the mortality and morbidity rate of oral cancer by investing our time and expertise in early intervention.” You can read her full article Early intervention a key in oral cancer prevention here.

We encourage you to take the coming month to educate those around you, and share the importance of Oral Cancer Awareness!

Oral cancer and other diseases that impede your ability to chew and swallow healthy foods can have a profound impact on the overall health and well being of a patient.

For a very long time, the inability to chew and swallow food was a potentially lethal condition. As modern medicine has advanced, we have gained the ability to provide the basic nutrients required to live.  The ingredients in many feeding tube solutions include different forms of sugar, and lots of chemicals, but do not have ‘real food’.

This problem was brought to Robin Gentry McGee’s attention first hand, after her father suffered a brain injury and was put on a feeding tube. Robin is a professional chef familiar with organic whole foods, and she immediately set to work creating a formula to help with her father’s brain injury and secondary complications. After six weeks on her new feeding tube formula, her father stabilized and improved, while reducing the number of medications he was on from seventeen down to two.

According to Robin, “This experience even further rooted my feeling that food has the innate power to both harm and heal. I deeply believe that from my father’s suffering he gave not only a great gift to me, but to the world. And I hope to share with as many people as possible.”

You can read more about this remarkable story in her new book “A Turn for the Worst: Traumatic Brain Injury and a Daughter’s Search for Answers,” or you may be able to catch her at the next Food As Medicine conference. She launched her product under the company name Functional Formularies to make her Whole foods feeding tube formula available to more people.

As the saying goes, ‘You are what you eat’. It is time to bring nutrition and quality ingredients to the people that need them the most. If you know someone that has difficulty eating or swallowing food, please make sure they are getting the most nutritious food possible, because it really can make a difference.